Table 2.

Experimental Group Design

Control	0 mg/ml MTA + 10% FBS α-MEM
MTA	0.2 mg/ml MTA + 10% FBS α-MEM
MTA + SB203580	0.2 mg/ml MTA + 10% FBS α-MEM + SB203580(20 μM)
MTA + U0126	0.2 mg/ml MTA + 10% FBS α-MEM + U0126(20 μM)

SB203580, inhibitor of p38; U0126, inhibitor of ERK